How health technology reassessment can support disinvestment in China’s national drug reimbursement list

A requirement to assess actual use of reimbursed medicines would enable transparent, documented, evidence based decisions on disinvestment, say Lizheng Shiand colleagues

Saved in:
Bibliographic Details
Published in:BMJ (Online) 2023-06, Vol.381, p.e068917-e068917
Main Authors: Shi, Lizheng, Wu, Jiuhong, Meng, Qingyue, Li, Dakui
Format: Article
Language:English
Subjects:
Analysis
Antihypertensives
Contract negotiations
Costs
Decision making
Drug use
Economic conditions
Health care policy
Health insurance
Impact analysis
Insurance coverage
Reimbursement
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A requirement to assess actual use of reimbursed medicines would enable transparent, documented, evidence based decisions on disinvestment, say Lizheng Shiand colleagues
ISSN:1756-1833
0959-8138
1756-1833
DOI:10.1136/bmj-2021-068917